Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 18;11(6):664.
doi: 10.3390/genes11060664.

Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler

Affiliations

Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler

Soon Keong Wee et al. Genes (Basel). .

Abstract

There is an ongoing worldwide coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At present, confirmatory diagnosis is by reverse transcription polymerase chain reaction (RT-PCR), typically taking several hours and requiring a molecular laboratory to perform. There is an urgent need for rapid, simplified, and cost-effective detection methods. We have developed and analytically validated a protocol for direct rapid extraction-free PCR (DIRECT-PCR) detection of SARS-CoV-2 without the need for nucleic acid purification. As few as six RNA copies per reaction of viral nucleocapsid (N) gene from respiratory samples such as sputum and nasal exudate can be detected directly using our one-step inhibitor-resistant assay. The performance of this assay was validated on a commercially available portable PCR thermocycler. Viral lysis, reverse transcription, amplification, and detection are achieved in a single-tube homogeneous reaction within 36 min. This minimizes hands-on time, reduces turnaround-time for sample-to-result, and obviates the need for RNA purification reagents. It could enable wider use of Covid-19 testing for diagnosis, screening, and research in countries and regions where laboratory capabilities are limiting.

Keywords: Covid-19; DIRECT-PCR; Diagnostics; Point-of-care; SARS-CoV-2; portable PCR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Amplification plot of SARS-CoV-2 N gene ssRNA control in (A) water, (B) spiked in sputum, and (C) spiked in nasal exudate conducted in the same thermocycler run. Numbers indicated the log10 copy number of the template present. No amplification was observed in the NTC. (D) Comparison of DIRECT-PCR assay amplification of SARS-CoV-2 N gene ssRNA control (blue line), N gene spiked in sputum (red line) and N gene spiked in nasal exudate (black line). Templates were ten-fold diluted in 8 orders of magnitude. Two microliters of template was used in 20 µL of PCR mastermix on the benchtop thermocycler. The amplification efficiency (E) was determined by plotting of mean Cq values against log10 copy number calculated using theoretical molarity of templates.
Figure 2
Figure 2
Fast DIRECT-PCR assay amplification efficiency of SARS-CoV-2 N gene plasmid spiked in sputum (red line) and N gene plasmid spiked in nasal exudate (black line) using the benchtop thermocycler (solid line) and the portable thermocycler (dotted line). Templates were ten-fold diluted in 6 orders of magnitude. One microliter of template was used in 10 µL of PCR mastermix.
Figure 3
Figure 3
Workflow of fast DIRECT-PCR protocol for the direct detection of SARS-CoV-2. Covid-19 infection can be confirmed in less than an hour after sample collection and addition to mastermix for amplification and detection.

Similar articles

Cited by

References

    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. WHO WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. [(accessed on 12 March 2020)]; Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re....
    1. WHO COVID-19 Dashboard. [(accessed on 16 April 2020)]; Available online: https://covid19.who.int/
    1. Beeching N.J., E Fletcher T., Beadsworth M.B.J. Covid-19: Testing times. BMJ. 2020;369:m1403. doi: 10.1136/bmj.m1403. - DOI - PubMed
    1. Ng Y., Li Z., Chua Y.X., Chaw W.L., Zhao Z., Er B., Pung R., Chiew C.J., Lye D.C., Heng D., et al. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020;69:307–311. doi: 10.15585/mmwr.mm6911e1. - DOI - PMC - PubMed

Publication types